We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Analysis of electroencephalogram characteristics of anti-NMDA receptor encephalitis patients in China.
OBJECTIVE: To explore the characteristics of electroencephalogram (EEG) in patients with anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis.
METHODS: Anti-NMDAR encephalitis patients admitted to the Department of Neurology between January 2012 and June 2016 were enrolled. All patients underwent electroencephalogram (EEG) at least once in the disease peak stage, and received tumor screening, symptomatic therapy, and immunotherapy. Patients received outcome evaluation every 6months after the immunotherapy, and modified Rankin scale (mRS) 0-2 was defined as favorable outcome.
RESULTS: This study enrolled 62 cases of anti-NMDAR encephalitis patients, including 29 males (46.8%) and 33 females (53.2%). The patient ages were between 10 and 59 (mean 26.3±11.3) years. A total of 93 instances of EEG monitoring were performed on 62 patients. At the peak stage, EEG presentations showed 61 cases (98.4%) were abnormal, cranial MRI showed 29 cases (46.8%) were abnormal among all 62 patients. The main presentations of abnormal EEG were diffuse slowing (25 cases, 40.3%), epileptiform discharges (11 cases, 17.7%), extreme delta brush (EDB) (10 cases, 16.1%), polymorphic delta rhythm (6 cases, 9.7%), focal slowing (5 cases, 8.1%), and diffuse beta activities (4 cases, 6.5%). Patients with normal background, epileptiform discharges, polymorphic delta rhythm, and diffuse beta activity in EEG all had favorable long-term outcome.
CONCLUSIONS: The majority of anti-NMDAR encephalitis patients had abnormal EEG. EEG could sensitively reflect the abnormal brain functions of patients and could assist with early clinical diagnosis and prognosis prediction.
SIGNIFICANCE: Diffuse slowing was the most common presentation on the EEG in patients with anti-NMDAR encephalitis. The EEG pattern of normal background, epileptiform discharges, polymorphic delta rhythm, and diffuse beta activities at the peak stage might suggest favorable long-term prognosis.
METHODS: Anti-NMDAR encephalitis patients admitted to the Department of Neurology between January 2012 and June 2016 were enrolled. All patients underwent electroencephalogram (EEG) at least once in the disease peak stage, and received tumor screening, symptomatic therapy, and immunotherapy. Patients received outcome evaluation every 6months after the immunotherapy, and modified Rankin scale (mRS) 0-2 was defined as favorable outcome.
RESULTS: This study enrolled 62 cases of anti-NMDAR encephalitis patients, including 29 males (46.8%) and 33 females (53.2%). The patient ages were between 10 and 59 (mean 26.3±11.3) years. A total of 93 instances of EEG monitoring were performed on 62 patients. At the peak stage, EEG presentations showed 61 cases (98.4%) were abnormal, cranial MRI showed 29 cases (46.8%) were abnormal among all 62 patients. The main presentations of abnormal EEG were diffuse slowing (25 cases, 40.3%), epileptiform discharges (11 cases, 17.7%), extreme delta brush (EDB) (10 cases, 16.1%), polymorphic delta rhythm (6 cases, 9.7%), focal slowing (5 cases, 8.1%), and diffuse beta activities (4 cases, 6.5%). Patients with normal background, epileptiform discharges, polymorphic delta rhythm, and diffuse beta activity in EEG all had favorable long-term outcome.
CONCLUSIONS: The majority of anti-NMDAR encephalitis patients had abnormal EEG. EEG could sensitively reflect the abnormal brain functions of patients and could assist with early clinical diagnosis and prognosis prediction.
SIGNIFICANCE: Diffuse slowing was the most common presentation on the EEG in patients with anti-NMDAR encephalitis. The EEG pattern of normal background, epileptiform discharges, polymorphic delta rhythm, and diffuse beta activities at the peak stage might suggest favorable long-term prognosis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app